Stevanato Group (STVN) Q4 2025 earnings review
High-Value Mix Powers Margin Expansion Despite Engineering Drag
Stevanato Group delivered a solid Q4 with 5% YoY revenue growth (7% constant currency) to €346.5 million. The overarching story is a massive product mix shift: High-Value Solutions (HVS) surged 31% to a record 49% of total revenue. This structural shift toward premium biologic packaging drove a 120-bps expansion in consolidated gross margins, masking deep, ongoing struggles in the Engineering segment, where sales plummeted 23%. With Free Cash Flow finally turning positive for the year and strong FY26 guidance calling for double-digit earnings growth, management's strategic pivot toward high-margin biologics and GLP-1s is successfully offsetting legacy business weaknesses.
🐂 Bull Case
High-Value Solutions grew 31% YoY and now account for nearly half of the company's revenue. This structural shift is successfully driving gross margin expansion (up 120 bps in Q4) despite macro headwinds.
The booming GLP-1 market now represents 19-20% of Stevanato's total revenue. The company's specialized containment products (EZ-fill, Nexa) are deeply embedded in these high-growth secular trends.
🐻 Bear Case
The Engineering division remains in freefall, with Q4 sales down 23% and operating margins compressing to just 9.1%. Slower order conversions and unfavorable project mixes continue to drag on total corporate performance.
Revenue from 'other containment and delivery solutions' fell 9% in Q4. While management cites a deliberate transition to high-value products, this signals that the base bulk vial business remains weak.
⚖️ Verdict: 🟢
Bullish. The strategic transition is working. The explosive growth in High-Value Solutions and the resulting margin expansion are more than enough to offset the cyclical weakness in the Engineering segment. Positive free cash flow and confident FY26 guidance confirm the core engine is healthy.
Key Themes
High-Value Solutions (HVS) Dominance
Accelerating. HVS is the primary growth engine for Stevanato. In Q4, HVS revenue jumped 31% YoY to a record €171.4 million. Crucially, HVS now represents 49% of total company revenue (up from 39% a year ago). This premium mix, driven by demand for EZ-fill vials and Nexa syringes, is the direct cause of the company's 120-bps gross margin expansion in the quarter.
Secular Tailwinds: GLP-1 and Biologics
Stable. The macro tailwind from the biologics market is immense. Management disclosed that GLP-1 drugs represented approximately 19% to 20% of total company revenue in FY25. Stevanato's ability to secure a 'fair share' of the global GLP-1 packaging market validates its quality standards and supply chain security.
Engineering Segment Deterioration
Decelerating. The Engineering division's performance worsened significantly in Q4, with revenue dropping 23% YoY to €39.4 million. Gross profit margin collapsed by 280 basis points to 15.8%. Management attributes this to lower volumes of new work and an unfavorable project mix. The turnaround timeline remains highly uncertain.
Legacy Containment Revenues Shrinking
Reversing. While HVS surged, revenue from 'other containment and delivery solutions' decreased 9% YoY to €135.7 million in Q4. Management framed this as a deliberate transition away from lower-value bulk products, but this contraction limits total top-line growth and suggests traditional vial demand remains subdued.
Scaling New U.S. and Italian Facilities
Accelerating. The new manufacturing facilities in Fishers, Indiana, and Latina, Italy, are scaling commercial production. While management noted these plants remain currently 'dilutive to the corporate margin,' they highlighted operational improvements and better utilization. These plants are critical for securing U.S. supply chains and mitigating geopolitical tariff risks.
Reported Net Profit Declined Despite Margin Expansion
Stable. A contradictory data point to the bullish margin narrative: despite a 5% increase in revenue and a 120-bps bump in gross margin, Q4 GAAP Net Profit actually fell 1.6% YoY to €47.6 million. This was driven by a sharp drop in finance income (€0.3M vs €5.6M last year) and higher income taxes (€18.2M vs €16.3M), showing that below-the-line items are currently eating up operational gains.
Other KPIs
Reversing. A major milestone for the company. After burning €148.5 million in FY24 due to massive capacity build-outs, FCF turned positive in FY25. Operating cash flow surged to €286.1 million (up from €155.8M), comfortably covering the €275.1M in capital expenditures.
Accelerating. Up 70 basis points year-over-year. The margin profile continues to strengthen as the mix of high-value solutions increases, offsetting the margin drag from the underperforming Engineering segment and the start-up costs of new plants.
Stable. CapEx remains elevated as the company finishes outfitting its Fishers, Indiana, and Latina, Italy facilities. Management continues to aggressively invest in future capacity despite near-term margin dilution from these assets.
Guidance
Stable. The midpoint of €1.275 billion implies a ~7.5% YoY growth rate. This is roughly consistent with the 7% reported growth achieved in FY25, indicating management expects steady, continuous demand without any massive step-ups or step-downs.
Accelerating. The midpoint of €339.35 million implies a ~13.9% YoY growth rate compared to FY25's €298.0 million. EBITDA is guided to grow roughly twice as fast as revenue, signaling management's strong confidence in continued margin expansion driven by product mix and improved plant utilization.
Accelerating. The midpoint of €0.61 implies a ~13% YoY growth rate over FY25's €0.54. This aligns with the EBITDA growth trajectory and highlights strong flow-through to the bottom line.
Key Questions
Margin Accretion Timeline for New Plants
You noted that the Fishers and Latina facilities remain dilutive to corporate margins. What is the specific utilization threshold or timeline required for these plants to cross over and become margin-accretive?
Engineering Segment Trough
With Engineering revenue down 23% and margins collapsing, have we reached the bottom for this segment? What specific leading indicators in your pipeline suggest a stabilization in FY26?
Legacy Containment Declines
Revenue from 'other containment' fell 9% this quarter. How much of this decline is due to a deliberate strategic exit from lower-value bulk products versus competitive pricing pressures or residual market destocking?
Tariff and FX Mitigation
Gross margins expanded impressively despite mentions of unfavorable foreign currency translation and tariffs. Looking into FY26, are you actively raising prices to offset these headwinds, or relies solely on the HVS mix shift?